Gapping up
In reaction to earnings/guidance:
- DHR +17.7%, CLPT +11.9%, STIM +11.6%, ACLS +6.5% (guides Q4 above consensus; also announces new $100 mln share repurchase program), KBH +4.8%, BHC +4.8%, VAPO +2.9%, RILY +2.8% (raises guidance for Q4; also announces stok offering), CSTL +1.3%, INFO +1.2%
Other news:
- MTRX +27.4% (signs deal with GTLS for hydrogen systems)
- TEF +9.2% (American Tower enters Telxius Towers Transaction with Telefonica)
- DMTK +8.4% (announces inclusion of genomic patch testing in national guidelines)
- MRNS +7.1% (receives positive response from FDA on sufficiency of one phase 3 clinical trial for filing of new drug application (NDA) for the use of ganaxolone in CDKL5 deficiency disorder)
- HARP +7% (FDA has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma; Co is planning to present interim data from the ongoing Phase 1/2 dose escalation trial later this year)
- MRSN +6.4% (Bain Capital slightly increases active passive stake to 4.8%)
- TLSA +6.3% (appoints Dr Neil Graham as Chief Medical Officer)
- ALLY +6.1% (authorizes $1.6 bln stock repurchase program)
- STPK +5.3% (awarded project to deliver smart energy storage to massachusetts water resource authority)
- DOCU +3.7% (prices increased offering of $600.0 mln of 0% convertible senior notes due 2024 (prior $500 mln) for net proceeds of ~$588.9 mln)
- NKLA +3.6% (secures "innovative" electric rate schedule in Arizona)
- ATNM +3.1% (announced the research collaboration with Astellas)
- EVER +2.9% (names new Chief Technology Officer)
- RILY +2.8% (priced an underwritten registered public offering of 1,228,735 shares of its common stock at a price to the public of $46.00/share)
- REGN +2.7% (announces sale of additional COVID-19 antibody cocktail doses to US govt)
- ALLT +2.6% (selected by Tier-1 European mobile provider to provide cybersecurity services)
- BW +2.3% (awarded $8 mln contract for high-efficiency air-cooled condenser for U.K. waste-to-energy plant)
- WBA +1.2% (makes majority investment in iA, a supplier of pharmacy automation software)
Analyst comments:
- SPB +3.4% (upgraded to Buy from Hold at Deutsche Bank)
- CVLT +3.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- SWCH +3.1% (upgraded to Buy from Hold at Jefferies)
- AMBA +2.4% (upgraded to Buy from Neutral at ROTH Capita)
- MBUU +1.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- MA +1.2% (upgraded to Buy from Hold at Jefferies)
- TWTR +1.2% (upgraded to Buy from Neutral at MKM Partners)
- SBRA +1.1% (upgraded to Buy from Hold at Jefferies)
- HD +0.8% (upgraded to Buy from Neutral at Guggenheim)
- XOM +0.7% (upgraded to Overweight from Neutral at JP Morgan)